abstract |
An anticancer agent for use in a treatment procedure to a subject who has a colorectal cancer with a fusion of the kinesin-5B-proto-oncogene RET family member (KIF5B-RET), in which the procedure comprises: administering to the subject an effective amount of the anticancer agent, thereby treating colorectal cancer in the subject, in which the anticancer agent is selected from: (i) a multiple kinase inhibitor or a specific RET inhibitor; or (ii) a nucleic acid molecule selected from the group consisting of antisense molecules, ribozymes, siRNA and triple helix molecules, in which the nucleic acid molecule hybridizes to a nucleic acid molecule encoding the KIF5B-RET fusion , thereby blocking or reducing the mRNA expression of the nucleic acid molecule encoding the KIF5B-RET fusion. |